389 related articles for article (PubMed ID: 12874285)
1. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX.
Liu S; Guo R; Simpson LG; Xiao ZS; Burnham CE; Quarles LD
J Biol Chem; 2003 Sep; 278(39):37419-26. PubMed ID: 12874285
[TBL] [Abstract][Full Text] [Related]
2. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization.
Quarles LD
Am J Physiol Endocrinol Metab; 2003 Jul; 285(1):E1-9. PubMed ID: 12791601
[TBL] [Abstract][Full Text] [Related]
3. Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice.
Liu S; Tang W; Zhou J; Vierthaler L; Quarles LD
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1636-44. PubMed ID: 17848631
[TBL] [Abstract][Full Text] [Related]
4. Pathogenic role of Fgf23 in Hyp mice.
Liu S; Zhou J; Tang W; Jiang X; Rowe DW; Quarles LD
Am J Physiol Endocrinol Metab; 2006 Jul; 291(1):E38-49. PubMed ID: 16449303
[TBL] [Abstract][Full Text] [Related]
5. Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling.
Martin A; Liu S; David V; Li H; Karydis A; Feng JQ; Quarles LD
FASEB J; 2011 Aug; 25(8):2551-62. PubMed ID: 21507898
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of the DMP1 C-terminal fragment stimulates FGF23 and exacerbates the hypophosphatemic rickets phenotype in Hyp mice.
Martin A; David V; Li H; Dai B; Feng JQ; Quarles LD
Mol Endocrinol; 2012 Nov; 26(11):1883-95. PubMed ID: 22930691
[TBL] [Abstract][Full Text] [Related]
7. The wrickkened pathways of FGF23, MEPE and PHEX.
Rowe PS
Crit Rev Oral Biol Med; 2004 Sep; 15(5):264-81. PubMed ID: 15470265
[TBL] [Abstract][Full Text] [Related]
8. Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway.
Rowe PS
Crit Rev Eukaryot Gene Expr; 2012; 22(1):61-86. PubMed ID: 22339660
[TBL] [Abstract][Full Text] [Related]
9. Hexa-D-arginine treatment increases 7B2•PC2 activity in hyp-mouse osteoblasts and rescues the HYP phenotype.
Yuan B; Feng JQ; Bowman S; Liu Y; Blank RD; Lindberg I; Drezner MK
J Bone Miner Res; 2013 Jan; 28(1):56-72. PubMed ID: 22886699
[TBL] [Abstract][Full Text] [Related]
10. Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity.
Liu S; Rowe PS; Vierthaler L; Zhou J; Quarles LD
J Endocrinol; 2007 Jan; 192(1):261-7. PubMed ID: 17210763
[TBL] [Abstract][Full Text] [Related]
11. A Phex mutation in a murine model of X-linked hypophosphatemia alters phosphate responsiveness of bone cells.
Ichikawa S; Austin AM; Gray AK; Econs MJ
J Bone Miner Res; 2012 Feb; 27(2):453-60. PubMed ID: 22006791
[TBL] [Abstract][Full Text] [Related]
12. Osteocyte-specific deletion of Fgfr1 suppresses FGF23.
Xiao Z; Huang J; Cao L; Liang Y; Han X; Quarles LD
PLoS One; 2014; 9(8):e104154. PubMed ID: 25089825
[TBL] [Abstract][Full Text] [Related]
13. Analysis of recombinant Phex: an endopeptidase in search of a substrate.
Guo R; Liu S; Spurney RF; Quarles LD
Am J Physiol Endocrinol Metab; 2001 Oct; 281(4):E837-47. PubMed ID: 11551862
[TBL] [Abstract][Full Text] [Related]
14. Complex intrinsic abnormalities in osteoblast lineage cells of X-linked hypophosphatemia: Analysis of human iPS cell models generated by CRISPR/Cas9-mediated gene ablation.
Nakanishi T; Yamazaki M; Tachikawa K; Ueta A; Kawai M; Ozono K; Michigami T
Bone; 2024 Apr; 181():117044. PubMed ID: 38331306
[TBL] [Abstract][Full Text] [Related]
15. Proteolytic processing of osteopontin by PHEX and accumulation of osteopontin fragments in Hyp mouse bone, the murine model of X-linked hypophosphatemia.
Barros NM; Hoac B; Neves RL; Addison WN; Assis DM; Murshed M; Carmona AK; McKee MD
J Bone Miner Res; 2013 Mar; 28(3):688-99. PubMed ID: 22991293
[TBL] [Abstract][Full Text] [Related]
16. ASARM peptides: PHEX-dependent and -independent regulation of serum phosphate.
David V; Martin A; Hedge AM; Drezner MK; Rowe PS
Am J Physiol Renal Physiol; 2011 Mar; 300(3):F783-91. PubMed ID: 21177780
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of Phex in osteoblasts fails to rescue the Hyp mouse phenotype.
Liu S; Guo R; Tu Q; Quarles LD
J Biol Chem; 2002 Feb; 277(5):3686-97. PubMed ID: 11713245
[TBL] [Abstract][Full Text] [Related]
18. Excessive Osteocytic Fgf23 Secretion Contributes to Pyrophosphate Accumulation and Mineralization Defect in Hyp Mice.
Murali SK; Andrukhova O; Clinkenbeard EL; White KE; Erben RG
PLoS Biol; 2016 Apr; 14(4):e1002427. PubMed ID: 27035636
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of human PHEX under the human beta-actin promoter does not fully rescue the Hyp mouse phenotype.
Erben RG; Mayer D; Weber K; Jonsson K; Jüppner H; Lanske B
J Bone Miner Res; 2005 Jul; 20(7):1149-60. PubMed ID: 15940367
[TBL] [Abstract][Full Text] [Related]
20. FGF23 and its role in X-linked hypophosphatemia-related morbidity.
Beck-Nielsen SS; Mughal Z; Haffner D; Nilsson O; Levtchenko E; Ariceta G; de Lucas Collantes C; Schnabel D; Jandhyala R; Mäkitie O
Orphanet J Rare Dis; 2019 Feb; 14(1):58. PubMed ID: 30808384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
